Technology | March 25, 2011

FDA Clears Gamma Ray Stereotactic Neurosurgery System

March 25, 2011 – The U.S. Food and Drug Administration (FDA) has cleared a gamma ray neurosurgery system. The Infini system, from Masep Infini, reduces procedure times and can increase patient throughput.

It features independent beam switch control with programmable arcs, automated collimator exchange and three-dimensional patient positioning and the company’s Rotary Focusing technology. Independent beam switch control with programmable arcs allows for fine-tuning of dose distributions to address even the most challenging cases. Automated collimator exchange and three-dimensional patient positioning allow radiosurgery to be conducted without the need to interrupt procedures to manually exchange collimators or re-position patients. Treatment can also be initiated by the simple push of a button.

The patented Rotary Focusing technology provides customers with reduced system acquisition and maintenance costs. It allows the system to operate with fewer cobalt sources than comparable fixed cobalt source systems without compromising total activity levels.

"The Infini is a welcome addition to the field of gamma ray radiosurgery," said Edward Laws, M.D., director of the Pituitary and Neuroendocrine Center at Brigham and Women's Hospital in Boston. "For patients with indications for gamma ray radiosurgery and for hospitals and clinics who provide it, there was really only one option available and not all healthcare systems could meet the acquisition and replacement costs of this type of equipment. Masep Infini's new system meets the technological requirements neurosurgeons demand but in an affordable, practical package."

Stereotactic gamma ray neurosurgery focuses radiation on specific areas of the brain to treat tumors and lesions. The head is held stationary using special headgear. The patient is then positioned and re-positioned inside the system during the treatment, which is painless and silent. The surgery does not require an incision, and is typically an outpatient procedure.

For more information: www.masepinfini.com

Related Content

ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...
360_NW_Proton_Center_Gantry_Room_Back_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 photo view behind the gantry room at the ...
360_NW_Proton_Center_Inclined_Room_THUMBNAIL
360 Photos | 360 View Photos | February 28, 2019
This is a 360 view of Treatment Room 3 (of 4) at the N...
NW Proton Center Gantry Room Front
360 Photos | 360 View Photos | February 27, 2019
This is a 360 photo view inside the gantry room at the...
Videos | Proton Therapy | February 26, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...